ERLOCIP ERLOTINIB 150 MG TABLETS

Get a Price/Quote

ERLOCIP ERLOTINIB 150 MG TABLETS Specification

Pacakaging (Quantity Per Box)
30 Tablets

Indication
Locally advanced or metastatic non-small cell lung cancer (NSCLC), metastatic pancreatic cancer

Origin of Medicine
India

Dosage Form
Oral

Salt Composition
Erlotinib 150mg

Drug Type
Allopathic

Ingredients
Erlotinib Hydrochloride

Physical Form
Tablets

Function
Anticancer medicine (EGFR inhibitor)

Recommended For
Non-Small Cell Lung Cancer, Pancreatic Cancer

Dosage
As prescribed by physician

Dosage Guidelines
Take on empty stomach, at least 1 hour before or 2 hours after food

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store below 30C, protect from light and moisture

ERLOCIP ERLOTINIB 150 MG TABLETS Trade Information

Packaging Details
PACK OF 30 TABLETS

About ERLOCIP ERLOTINIB 150 MG TABLETS

Erlocip 150 Mg Tablets - Erlotinib Hydrochloride

Erlocip Tablets Contains Erlotinib And Its Available As : 100 Mg & 150 Mg Tablets.

Specification :-

Product Name : Erlocip.
Content : Erlotinib Hcl.
Form : Tablets.
Strength : 100 Mg & 150 Mg.
Packing : Pack Of 30 Tablets.
Manufactured By : Cipla.

Note :-Erlocip Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug..............

Usage and Dosage Guidelines

ERLOCIP 150 tablets are to be taken orally, precisely as directed by your healthcare provider. For optimal absorption, these tablets should be consumed at least one hour before or two hours after meals. Your physician will prescribe the appropriate dosage based on your specific condition and response to therapy. Do not alter the dose or frequency without consulting your doctor.

Therapeutic Benefits and Indications

This medication is primarily prescribed for patients diagnosed with non-small cell lung cancer (NSCLC) that is locally advanced or metastatic, as well as for those with metastatic pancreatic cancer. By inhibiting EGFR, ERLOCIP 150 disrupts cancer cell growth and can improve treatment outcomes. Always discuss anticipated benefits and expectations with your oncologist.

Safety and Precautions

ERLOCIP 150 should not be used by pregnant or breastfeeding women unless specifically instructed by a physician. Common side effects may include rash, diarrhea, loss of appetite, or fatigue. The drug is manufactured in a WHO GMP Certified facility and adheres to rigorous safety standards. Regular monitoring and follow-ups are essential during therapy to manage possible adverse effects.

FAQs of ERLOCIP ERLOTINIB 150 MG TABLETS:

Q: How should ERLOCIP ERLOTINIB 150 MG TABLETS be taken for best results?

A: These tablets should be swallowed whole with water, on an empty stomach, at least one hour before or two hours after eating. Follow your physicians directions regarding dosage and timing for optimal effectiveness.

Q: What conditions are treated with ERLOCIP 150?

A: ERLOCIP 150 is prescribed for locally advanced or metastatic non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer, helping to inhibit the growth and spread of cancer cells by targeting EGFR pathways.

Q: When should I contact my doctor while using ERLOCIP 150?

A: Contact your doctor if you experience persistent side effects such as severe rash, diarrhea, fatigue, or loss of appetite, or if you have concerns about any new or worsening symptoms during treatment.

Q: Where should ERLOCIP 150 tablets be stored?

A: Keep ERLOCIP 150 tablets below 30C, away from light and moisture. Store them in the original packaging and out of reach of children.

Q: What is the process for obtaining ERLOCIP 150 tablets?

A: ERLOCIP 150 requires a valid prescription from a licensed physician. Once prescribed, it can be obtained from authorized pharmacies or medical suppliers.

Q: What are the benefits of using ERLOCIP 150 for cancer patients?

A: By inhibiting the EGFR tyrosine kinase, ERLOCIP 150 can help slow the progression of certain cancers, potentially improving survival outcomes and quality of life when used as part of a prescribed treatment regimen.

Tell us about your requirement